GLP-1 weight-loss pills appear to be just as effective as injections, with clinical trials showing similar average weight ...

As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful ...

The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the risk of serious kidney injury that can result from dehydration. This comes ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. The U.S. Food and Drug Administration (FDA) recently ...

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending for the first time, according to a March 25 report from Evernorth. The ...

One in eight Americans is currently taking a GLP-1 to lose weight or treat a chronic condition.

Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery ...

Glucagon-like peptide-1 (GLP-1) agonists have transformed weight loss treatments. However, about half of the patients who take these drugs stop within a year because of unwanted side effects. 1,2 For ...

As the buzz around GLP-1 medications grew to a fever pitch over the past two years, many digital health and telehealth companies quickly added programs to prescribe anti-obesity drugs. Omada Health ...

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry ...

In 2026, Robert F. Kennedy Jr.'s health policy changes will start playing out on GLP-1s, dietary guidelines, and rural health ...